Clinical synergism from combinatorial VEGF signal transduction inhibition in patients with advanced solid tumors - early results from a phase I study of sorafenib (BAY 43-9006) and bevacizumab

被引：0
|
作者：
Posadas, E.
Kwitkowski, V.
Lie, M.
Kotz, H.
Minasian, L.
Sarosy, G.
Harold, N.
Fioravanti, S.
Kohn, E.
机构：
[1] NCI, Med Oncol Clin Res Unit, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, Bethesda, MD 20892 USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：419 / 420
页数：2
相关论文
共 50 条
  • [1] Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
    Richly, H
    Henning, BF
    Kupsch, P
    Passarge, K
    Grubert, M
    Hilger, RA
    Christensen, O
    Brendel, E
    Schwartz, B
    Ludwig, M
    Flashar, C
    Voigtmann, R
    Scheulen, ME
    Seeber, S
    Strumberg, D
    ANNALS OF ONCOLOGY, 2006, 17 (05) : 866 - 873
  • [2] BAY 43-9006: Early clinical data in patients with advanced solid malignancies
    Hotte, SJ
    Hirte, HW
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (25) : 2249 - 2253
  • [3] Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors
    Richly, H
    Kupsch, P
    Passarge, K
    Grubert, M
    Hilger, RA
    Haase, CG
    Schwartz, B
    Scheulen, ME
    Seeber, S
    Strumberg, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 207S - 207S
  • [4] Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors
    Kupsch, P
    Passarge, K
    Richly, H
    Wiesemann, K
    Hilger, RA
    Haase, CG
    Schwartz, B
    Scheulen, ME
    Seeber, S
    Strumberg, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 209S - 209S
  • [5] Phase I study to determine the safety and pharmacokinetics of BAY 43-9006 in patients with advanced refractory solid tumors.
    Hirte, H
    Moore, MJ
    Oza, AM
    Siu, LL
    Harris, H
    Maclean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3768S
  • [6] Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
    Ranieri, G.
    Gadaleta-Caldarola, G.
    Goffredo, V.
    Patruno, R.
    Mangia, A.
    Rizzo, A.
    Sciorsci, R. L.
    Gadaleta, C. D.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (07) : 938 - 944
  • [7] A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer
    Siu, LL
    Takimoto, CH
    Awada, A
    Moore, MJ
    Piccart, M
    Poulin-Costello, M
    Lathia, C
    Petrenciuc, O
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 209S - 209S
  • [8] A clinical phase I and biomarker study of the Raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumors
    Strumberg, D
    Voliotis, D
    Moeller, JG
    Hilger, RA
    Richly, H
    Beling, C
    Tewes, M
    Schleucher, N
    Scheulen, ME
    Seeber, S
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S53 - S54
  • [9] Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors
    Steinbild, S
    Baas, F
    Gmehling, D
    Brendel, E
    Christensen, O
    Schwartz, B
    Mross, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 220S - 220S
  • [10] Prospective study of positron emission tomography evaluating the activity of sorafenib (BAY 43-9006) in patients with advanced tumors.
    Kawada, K
    Murakami, K
    Sato, T
    Kojima, Y
    Ebi, H
    Kitagawa, K
    Kim, Y
    Araki, K
    Mukai, H
    Tahara, M
    Nakajima, H
    Nakajima, K
    Minami, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9062S - 9062S
12345